Paratus Sciences

Paratus Sciences is a biotechnology company that translates extreme biological adaptations found in nature into first-in-class medicines, focusing on cardiometabolic and immune and inflammatory diseases. Its central asset is a purpose-built, AI-centric discovery engine built on proprietary bat genomic and tissue-derived multi-omic data, human disease datasets and public mammalian genomic resources, used to identify novel targets and engineer differentiated therapeutics [0][3][7].

The company's disclosed pipeline spans immunology and inflammation (an inflammasome/ASC program and a group of additional targets) and cardiometabolism ("Target A" plus multiple undisclosed targets), with programs shown at target identification/validation and lead identification/optimization stages. The lead candidate, PS-1001, is described as a first-in-class pan-inflammasome inhibitor that neutralizes ASC, a scaffold protein of the inflammasome complex, with a dual mechanism that prevents assembly of new intracellular inflammasome complexes and disassembles existing extracellular complexes. PS-1001 was developed through a collaboration with Duke-NUS Medical School and is inspired by evolutionary adaptations that suppress excessive inflammasome activation [3][7].

A third-party startup directory profile describes Paratus as founded in 2021, headquartered in New York, with a Singapore subsidiary, a platform merging genomics, multi-omics, informatics and cell biology, and an associated Bat Biology Foundation supporting sample collection and bat research; the same profile reports one funding round totaling $100 million. That directory's figures (including an employee band of 1001-5000) are unverified by other sources here and conflict in part with company materials, which give Boston and Singapore as the datelines for corporate announcements [4][7].

Founding story

According to a third-party startup profile, Paratus emerged from the recognition that bats — an exceptionally diverse, stress-tolerant mammalian order with notable resistance to disease — carry evolved genomic and physiological adaptations that could reveal novel mechanisms translatable to human disease; the founders assembled genomics, informatics and translational drug discovery expertise to operationalize that insight and created the Bat Biology Foundation to enable sample access and research partnerships [4]. Company materials list Richard Young and Paul Matsudaira as co-founders and Emma Teeling and Linfa Wang as founding advisors [2].

Business model

Paratus is a therapeutics developer rather than a service or product-revenue business: it uses an internal discovery platform to identify targets and advance proprietary drug candidates, beginning with PS-1001, toward clinical development. Sources describe academic and institutional collaborations (for example with Duke-NUS Medical School) and a stated strategy of partnerships with academia and industry, but no commercial products or revenue are disclosed [3][4][7].